Recent Updates
Recently added Catalysts
GH Positive Sentiment

Business Insider Names Guardant Health One of America's Most Innovative Businesses

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health, Inc. has been recognized by Business Insider as one of America's Most Innovative Businesses for 2027. The company received a five-star rating, the highest available, and is among only 12 biotechnology research companies to achieve this distinction. This recognition highlights Guardant's innovative performance over the past five years.

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health recognized for innovation by Business Insider.
  • Achieved highest rating with five-star recognition.
  • Only 12 biotechnology companies received this honor.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~54 mo
Minimal dilution risk
Lead asset
NSAI+ CDK4/6i
Phase 3 · HR Positive/HER-2 Negative Breast Cancer

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Guardant am

Frequently Asked Questions

What recognition did Guardant Health receive?

Guardant Health was named one of America's Most Innovative Businesses for 2027.

How many companies received the five-star rating?

Only 12 biotechnology research companies received the five-star rating.

What does the Business Insider list recognize?

The list recognizes companies for their innovative performance over the past five years.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health biotechnology innovation Business Insider precision oncology
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~54 mo
Minimal dilution risk
Lead asset
NSAI+ CDK4/6iPhase 3
HR Positive/HER-2 Negative Breast Cancer →